Filtered By:
Cancer: Soft Tissue Sarcoma

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 24 results found since Jan 2013.

Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine.
In this report, we show that Ewing sarcoma cells are sensitive to treatment with clofarabine, which is a nucleoside analogue and allosteric inhibitor of RNR. However, clofarabine is a reversible inhibitor of RNR and we found that the effect of clofarabine is limited when using a short (6-hour) drug treatment. Gemcitabine, on the other hand, is an irreversible inhibitor of the RRM1 subunit of RNR and this drug induces apoptosis in Ewing sarcoma cells when used in both 6-hour and longer drug treatments. Treatment of Ewing sarcoma cells with gemcitabine also results in activation of checkpoint kinase 1 (CHK1), which is a crit...
Source: Oncotarget - November 22, 2017 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

CD31 Expression Determines Redox Status and Chemoresistance in Human Angiosarcomas.
CONCLUSIONS: Human AS contain a small aggressive CD31(low) population that have lost part of their endothelial differentiation programs and are more resistant against oxidative stress and DNA damage due to intensified YAP signaling. Our finding that the addition of YAP inhibitors can re-sensitize CD31(low) cells towards doxorubicin may aid in the rational development of novel combination therapies to treat AS. PMID: 29084920 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - October 30, 2017 Category: Cancer & Oncology Authors: Venkataramani V, Küffer S, Cheung KCP, Jiang X, Trümper LHP, Wulf GG, Ströbel P Tags: Clin Cancer Res Source Type: research

Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine.
In this report, we show that Ewing sarcoma cells are sensitive to treatment with clofarabine, which is a nucleoside analogue and allosteric inhibitor of RNR. However, clofarabine is a reversible inhibitor of RNR and we found that the effect of clofarabine is limited when using a short (6-hour) drug treatment. Gemcitabine, on the other hand, is an irreversible inhibitor of the RRM1 subunit of RNR and this drug induces apoptosis in Ewing sarcoma cells when used in both 6-hour and longer drug treatments. Treatment of Ewing sarcoma cells with gemcitabine also results in activation of checkpoint kinase 1 (CHK1), which is a crit...
Source: Oncotarget - July 9, 2017 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth.
Abstract Myxoid liposarcoma (MLS) is a soft tissue sarcoma characterized by a recurrent t(12;16) translocation. Although tumors are initially radio- and chemosensitive, the management of inoperable or metastatic MLS can be challenging. Therefore, our aim was to identify novel targets for systemic therapy. We performed an in vitro high-throughput drug screen using three MLS cell lines (402091, 1765092, DL-221), which were treated with 273 different drugs at four different concentrations. Cell lines and tissue microarrays were used for validation. As expected, all cell lines revealed a strong growth inhibition to co...
Source: Translational Oncology - June 24, 2017 Category: Cancer & Oncology Authors: de Graaff MA, Malu S, Guardiola I, Kruisselbrink AB, de Jong Y, Corver WE, Gelderblom H, Hwu P, Nielsen TO, Lazar AJ, Somaiah N, Bovée JVMG Tags: Transl Oncol Source Type: research

Identification of a Novel SYK/c-MYC/MALAT1 Signaling Pathway and Its Potential Therapeutic Value in Ewing Sarcoma.
CONCLUSIONS: The present study identifies a novel signaling involving SYK/c-MYC/MALAT1 as a promising therapeutic target for the treatment of EWS. PMID: 28336564 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - March 23, 2017 Category: Cancer & Oncology Authors: Sun H, Lin DC, Cao Q, Pang B, Gae DD, Lee VK, Lim HJ, Doan N, Said JW, Gery S, Chow M, Mayakonda A, Forscher C, Tyner JW, Koeffler HP Tags: Clin Cancer Res Source Type: research

GSE93677 Identification of a Novel SYK/c-MYC/MALAT1 Signaling Pathway and Its Potential Therapeutic Value in Ewing Sarcoma
Contributors : Haibo Sun ; De-Chen Lin ; Qi Cao ; Brenden Pang ; David-Hayon Gae ; Victor K Lee ; Huey J Lim ; Ngan Doan ; Jonathan W Said ; Sigal Gery ; Anand Mayakonda ; Charles Forscher ; Jeffery W Tyner ; Phillip H KoefflerSeries Type : Expression profiling by arrayOrganism : Homo sapiensEwing Sarcoma (EWS) is a devastating soft tissue sarcoma affecting predominantly young individuals. Tyrosine kinases (TKs) and associated pathways are continuously activated in many malignancies including EWS; these enzymes provide candidate therapeutic targets. Using two high-throughput screens with EWS cell lines (a siRNA library and...
Source: GEO: Gene Expression Omnibus - January 18, 2017 Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research

MLN-8237; A dual inhibitor of aurora A and B in soft tissue sarcomas.
Authors: Nair JS, Schwartz GK Abstract Aurora kinases have become an attractive target in cancer therapy due to their deregulated expression in human tumors. Liposarcoma, a type of soft tissue sarcoma in adults, account for approximately 20% of all adult soft tissue sarcomas. There are no effective chemotherapies for majority of these tumors. Efforts made to define the molecular basis of liposarcomas lead to the finding that besides the amplifications of CDK4 and MDM2, Aurora Kinase A, also was shown to be overexpressed. Based on these as well as mathematic modeling, we have carried out a successful preclinical stu...
Source: Oncotarget - February 19, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

EPHB4 tyrosine‐kinase receptor expression and biological significance in soft tissue sarcoma
Abstract Soft tissue sarcomas (STS) are heterogeneous malignant tumors of mesenchymal origin. Due to low incidence and high number of different histological subtypes, their pathogenesis and thus potential targets for their therapy remain barely investigated. Several studies revealed significant higher EPHB4 expression in malignancies such as prostate and colorectal cancer showing survival advantages for these tumor cells. Therefore we studied the expression of EPHB4 in a total of 46 clinical human specimens of different STS and human fibroblasts. EPHB4 mRNA and protein expression were significantly increased in synovial sa...
Source: International Journal of Cancer - October 1, 2014 Category: Cancer & Oncology Authors: M Becerikli, B Merwart, MC Lam, P Suppelna, A Rittig, A Mirmohammedsadegh, I Stricker, C Theiss, B.B. Singer, F Jacobsen, L Steinstraesser Tags: Carcinogenesis Source Type: research

Abstract 4725: Elevated co-expression of CCL2 and CX3CL1 is associated with apoptosis and good prognosis in soft tissue sarcoma patients
Conclusion: Our findings demonstrate that mRNA expression of CCL2 and CX3CL1 was significantly correlated with prognosis. Interestingly, there was a gender-specific impact of CCL2 on disease-specific survival. A significant decrease in apoptosis induction could be detected when cells were transfected with siRNA targeting CCL2 or CX3CL1 compared to the cells transfected with non-targeting siRNA. Citation Format: Elke Nolte, Astrid Kehlen, Thomas Greither, Sven Wach, Matthias Kappler, Matthias Bache, Hans-Jürgen Holzhausen, Christine Lautenschläger, Steffen Göbel, Peter Würl, Uta-Dorothee Immel, Abbas Agaimy, Bernd Wulli...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Nolte, E., Kehlen, A., Greither, T., Wach, S., Kappler, M., Bache, M., Holzhausen, H., Lautenschlager, C., Gobel, S., Wurl, P., Immel, U.–D., Agaimy, A., Wullich, B., Taubert, H. Tags: Clinical Research (Excluding Clinical Trials) Source Type: research